Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
GET POWR RATINGS... FREE!
XERS Price/Volume Stats
| Current price | $2.64 | 52-week high | $3.03 |
| Prev. close | $2.84 | 52-week low | $0.97 |
| Day low | $2.62 | Volume | 1,348,000 |
| Day high | $2.85 | Avg. volume | 1,265,556 |
| 50-day MA | $2.18 | Dividend yield | N/A |
| 200-day MA | $1.61 | Market Cap | 357.80M |
XERS Stock Price Chart Interactive Chart >
XERS POWR Grades
- XERS scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.75% of US stocks.
- XERS's strongest trending metric is Growth; it's been moving down over the last 179 days.
- XERS ranks lowest in Stability; there it ranks in the 7th percentile.
XERS Stock Summary
- XERIS BIOPHARMA HOLDINGS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 87.48% of US listed stocks.
- As for revenue growth, note that XERS's revenue has grown 91.23% over the past 12 months; that beats the revenue growth of 93% of US companies in our set.
- The volatility of XERIS BIOPHARMA HOLDINGS INC's share price is greater than that of 83.67% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to XERIS BIOPHARMA HOLDINGS INC, a group of peers worth examining would be TELA, XGN, TCX, DUOT, and KNDI.
- Visit XERS's SEC page to see the company's official filings. To visit the company's web site, go to www.xerispharma.com.
XERS Valuation Summary
- XERS's price/sales ratio is 3.2; this is 37.25% lower than that of the median Healthcare stock.
- XERS's price/sales ratio has moved down 244.2 over the prior 60 months.
Below are key valuation metrics over time for XERS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XERS | 2023-05-23 | 3.2 | 12.7 | -4.9 | -8.7 |
| XERS | 2023-05-22 | 3.3 | 13.5 | -5.2 | -9.1 |
| XERS | 2023-05-19 | 3.3 | 13.3 | -5.1 | -9.0 |
| XERS | 2023-05-18 | 3.2 | 12.8 | -5.0 | -8.8 |
| XERS | 2023-05-17 | 3.2 | 12.8 | -4.9 | -8.8 |
| XERS | 2023-05-16 | 3.2 | 13.0 | -5.0 | -8.9 |
XERS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XERS has a Quality Grade of D, ranking ahead of 9.9% of graded US stocks.
- XERS's asset turnover comes in at 0.208 -- ranking 192nd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows XERS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.208 | 0.661 | -0.415 |
| 2021-03-31 | 0.162 | 0.651 | -0.388 |
| 2020-12-31 | 0.134 | 0.544 | -0.482 |
| 2020-09-30 | 0.107 | 0.504 | -0.626 |
| 2020-06-30 | 0.046 | 0.218 | -0.894 |
| 2020-03-31 | 0.035 | 0.204 | -1.151 |
XERS Price Target
For more insight on analysts targets of XERS, see our XERS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Latest XERS News From Around the Web
Below are the latest news stories about XERIS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate XERS as an investment opportunity.
Q1 2023 Xeris Biopharma Holdings Inc Earnings CallQ1 2023 Xeris Biopharma Holdings Inc Earnings Call |
Xeris Biopharma Reports First Quarter 2023 Financial ResultsCHICAGO, May 09, 2023--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2023, and other corporate highlights. |
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are individual investors with 56% stake, while 33% is held by institutionsKey Insights Significant control over Xeris Biopharma Holdings by individual investors implies that the general public... |
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023CHICAGO, May 02, 2023--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Compa |
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ FormulationsCHICAGO, April 18, 2023--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.’ The claims in this newly issued patent cover certain pharmaceut |
XERS Price Returns
| 1-mo | 16.81% |
| 3-mo | 91.30% |
| 6-mo | 76.00% |
| 1-year | 16.81% |
| 3-year | -48.64% |
| 5-year | N/A |
| YTD | 98.50% |
| 2022 | -54.61% |
| 2021 | -40.45% |
| 2020 | -30.21% |
| 2019 | -58.53% |
| 2018 | N/A |
Continue Researching XERS
Want to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...